BLB(SZ:002286)2023-04-27 16:00Financial Performance - The company reported a total revenue of RMB 1.2 billion for the fiscal year 2022, representing a year-on-year growth of 15%[19]. - The company's operating revenue for 2022 was ¥2,712,745,317.35, a decrease of 1.89% compared to ¥2,764,976,972.69 in 2021[20]. - Net profit attributable to shareholders decreased by 33.94% to ¥133,168,839.10 in 2022 from ¥201,579,400.15 in 2021[20]. - Basic earnings per share fell by 33.33% to ¥0.36 in 2022, compared to ¥0.54 in 2021[20]. - The company reported a significant decline in quarterly net profit, with the fourth quarter showing ¥22,591,028.16, down from ¥48,028,304.48 in the second quarter[24]. - The company achieved a total revenue of 2.713 billion yuan in 2022, a year-on-year decrease of 1.89%[103]. - The net profit attributable to shareholders was 133.17 million yuan, down 33.94% compared to the previous year, primarily due to a supply-demand imbalance in competitive products like erythritol[103]. - The company reported a total revenue of 1.5 billion RMB for the fiscal year 2022, representing a year-over-year increase of 15%[185]. Dividend and Shareholder Information - The company plans to distribute a cash dividend of 0.8 yuan per 10 shares to all shareholders, based on a total of 371,812,900 shares[5]. - The company has not proposed any stock bonus or capital increase from reserves, focusing solely on cash dividends[5]. - The company's annual shareholder meeting had a participation rate of 32.26% on May 20, 2022[173]. - The first temporary shareholder meeting in 2022 had a participation rate of 20.31% on July 25, 2022[173]. - The second temporary shareholder meeting in 2022 had a participation rate of 32.15% on November 3, 2022[173]. Governance and Management - The company emphasizes the importance of accurate and complete financial reporting, with key personnel affirming the integrity of the annual report[4]. - The board of directors has fully attended the meeting to review the annual report, ensuring governance and oversight[5]. - The company’s governance structure complies with legal regulations, with no significant discrepancies noted[166]. - The company operates independently in business, personnel, assets, and finance, ensuring no interference from the controlling shareholder[167]. - The company experienced a change in management with the resignation of General Manager Wu Huaixiang on September 30, 2022, due to personal reasons[176]. - Xu Bei was elected as the new Supervisory Board Chairwoman on December 12, 2022, following the resignation of Xiong Shuqin[177]. - The management team is composed of experienced professionals with backgrounds in finance, engineering, and food science, enhancing the company's strategic capabilities[178]. Research and Development - Research and development expenses accounted for 8% of total revenue, reflecting the company's commitment to innovation and product development[19]. - The company has developed over 90 functional sugar products, expanding from a single product to a full range of offerings over 20 years of innovation[92]. - The company’s R&D investment amounted to ¥101,574,654.50 in 2022, representing a 0.96% increase from ¥100,613,062.55 in 2021, and accounted for 3.74% of total revenue[119]. - The company is developing new products such as D-alloheptulose and high-value lactose derivatives to meet market demands[116]. - The company is committed to enhancing its research and development capabilities in functional sugars to maintain its competitive edge in the market[154]. Market Expansion and Strategy - The company is exploring market expansion opportunities in Southeast Asia, targeting a revenue contribution of 5% from this region by 2024[19]. - The company plans to launch three new products in 2023, focusing on health supplements and functional foods, aiming for a 10% increase in market share[19]. - The company plans to continue expanding its investor outreach efforts to enhance market understanding and engagement[157]. - The company is planning to expand its market presence in Southeast Asia, targeting a 25% market share within the next three years[185]. - A strategic acquisition of a smaller biotech firm was completed, which is anticipated to enhance the company's product portfolio and increase market competitiveness[185]. Financial Health and Risks - The company has outlined potential risks in its future business operations, which investors are advised to consider[5]. - The net cash flow from operating activities dropped significantly by 85.06% to ¥30,821,782.60 in 2022, down from ¥206,267,702.76 in 2021[20]. - The company recognized non-recurring gains of ¥9,093,764.51 in 2022, compared to ¥37,209,655.04 in 2021[26]. - The company is exploring partnerships with international firms to enhance its global distribution network[160]. - The company recognizes risks associated with raw material price fluctuations, particularly for corn and sugar, and plans to mitigate these through futures hedging and improved production processes[152]. Product Development and Innovation - The company operates in the functional sugar industry, focusing on enzyme engineering and fermentation technology, with products widely used in health foods and pharmaceuticals[31]. - The company has achieved industrial production of various functional oligosaccharides, including isomalt oligosaccharides, fructooligosaccharides, galactooligosaccharides, and xylooligosaccharides, which are primarily used in functional foods, nutritional supplements, and the feed industry[35]. - The company has successfully developed and industrialized new products such as allulose and specific prebiotics, enhancing its functional sugar product system[81]. - The company aims to enhance its core product competitiveness through the industrialization of new sweetener products[116]. - The company is actively pursuing digital factory construction to enhance production transparency, traceability, and efficiency, thereby improving product quality[151]. Investor Relations - The company conducted multiple investor communications, including a site visit and conference calls, to discuss business conditions and industry developments[156]. - The company emphasized the importance of investor relations and transparency in its communications strategy[156]. - The company is dedicated to maintaining a strong relationship with its investors through regular updates and strategic discussions[156]. - The company highlighted its commitment to market expansion and potential mergers and acquisitions as part of its growth strategy[157]. Sustainability and Corporate Responsibility - The company has received multiple awards for its sustainability and quality, including recognition from Coca-Cola and other major partners[98]. - The company is positioned to benefit from national health policies aimed at improving public health and promoting healthy lifestyles[78]. - The company has established independent production and office locations, with no mixed operations with other entities[172].